Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...

Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.

AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of ...

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again ...

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.

But the company is not ruling out future deals, even in its metabolic unit, which recently saw a major partnership with ...